We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Experimental Drug Blocks Critical Lung Cancer DNA Repair Enzyme

By LabMedica International staff writers
Posted on 02 Jun 2015
Print article
Image: Structure of the DDX3X protein (Photo courtesy of Wikimedia Commons).
Image: Structure of the DDX3X protein (Photo courtesy of Wikimedia Commons).
A low molecular weight drug—effective on its own and in combination with radiation therapy—has been developed that interferes specifically with the cell cycle of lung cancer cells.

The drug, RK-33, was developed by investigators at Johns Hopkins University (Baltimore, MD, USA) to block the activity of the RNA helicase, DDX3 (DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked), which is overexpressed in many cancer types including lung cancer and is associated with lower survival in lung cancer patients.

The main function of helicases is to unpackage an organism's genes. They are motor proteins that move directionally along a nucleic acid phosphodiester backbone, separating two annealed nucleic acid strands (i.e., DNA, RNA, or RNA-DNA hybrid) using energy derived from ATP hydrolysis. There are many helicases due to the great variety of processes in which strand separation must be catalyzed. The human genome codes for 95 non-redundant helicases: 64 RNA helicases and 31 DNA helicases.

DDX3 is a member of the large DEAD-box protein family, which is defined by the presence of the conserved Asp-Glu-Ala-Asp (DEAD) motif, and has ATP-dependent RNA helicase activity. This protein has been reported to display a high level of RNA-independent ATPase activity, and unlike most DEAD-box helicases, the ATPase activity is thought to be stimulated by both RNA and DNA. This protein has multiple conserved domains and is thought to play roles in both the nucleus and cytoplasm. Overexpression of this gene has been implicated in tumor development.

The investigators synthesized the low molecular weight compound RK-33, which was designed to inhibit DDX3 by binding to the nucleotide-binding site within the enzyme. Results published in the May 2015 issue of the journal EMBO Molecular Medicine revealed that RK-33 binding inhibited DDX3's DNA repair function, which caused tumor cells to die and increased the efficacy of radiation therapy. RK-33 in combination with radiation induced tumor regression in multiple mouse models of lung cancer without causing damage to noncancerous tissues.

“We can lower the dose of radiation significantly but actually get more “bang for your buck” by pretreating lung cancer with RK-33,” said senior author Dr. Venu Raman, associate professor of radiology, radiological science, and oncology at Johns Hopkins University. “DDX3 is an extremely novel target associated with many cancer types and perturbing its function with a small molecule will enhance efficacy for cancer treatment. It is hard to find a magic bullet for cancer treatment, but because RK-33 is nontoxic and is a phenomenal radiosensitizer, there are so many opportunities.”

Related Links:

Johns Hopkins University


Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA
New
Rocking Shaker
HumaRock

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.